Included under terms of UK Non-commercial Government License.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Headline
Beta-interferon and glatiramer acetate were effective for the treatment of multiple sclerosis, with cost-effectiveness ranging from £7000 to £34,000 per quality-adjusted life-year.
Abstract
Background:
At the time of publication of the most recent National Institute for Health and Care Excellence (NICE) guidance [technology appraisal (TA) 32] in 2002 on beta-interferon (IFN-β) and glatiramer acetate (GA) for multiple sclerosis, there was insufficient evidence of their clinical effectiveness and cost-effectiveness.
Objectives:
To undertake (1) systematic reviews of the clinical effectiveness and cost-effectiveness of IFN-β and GA in relapsing–remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS) compared with best supportive care (BSC) and each other, investigating annualised relapse rate (ARR) and time to disability progression confirmed at 3 months and 6 months and (2) cost-effectiveness assessments of disease-modifying therapies (DMTs) for CIS and RRMS compared with BSC and each other.
Review methods:
Searches were undertaken in January and February 2016 in databases including The Cochrane Library, MEDLINE and the Science Citation Index. We limited some database searches to specific start dates based on previous, relevant systematic reviews. Two reviewers screened titles and abstracts with recourse to a third when needed. The Cochrane tool and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and Philips checklists were used for appraisal. Narrative synthesis and, when possible, random-effects meta-analysis and network meta-analysis (NMA) were performed. Cost-effectiveness analysis used published literature, findings from the Department of Health’s risk-sharing scheme (RSS) and expert opinion. A de novo economic model was built for CIS. The base case used updated RSS data, a NHS and Personal Social Services perspective, a 50-year time horizon, 2014/15 prices and a discount rate of 3.5%. Outcomes are reported as incremental cost-effectiveness ratios (ICERs). We undertook probabilistic sensitivity analysis.
Results:
In total, 6420 publications were identified, of which 63 relating to 35 randomised controlled trials (RCTs) were included. In total, 86% had a high risk of bias. There was very little difference between drugs in reducing moderate or severe relapse rates in RRMS. All were beneficial compared with BSC, giving a pooled rate ratio of 0.65 [95% confidence interval (CI) 0.56 to 0.76] for ARR and a hazard ratio of 0.70 (95% CI, 0.55 to 0.87) for time to disability progression confirmed at 3 months. NMA suggested that 20 mg of GA given subcutaneously had the highest probability of being the best at reducing ARR. Three separate cost-effectiveness searches identified > 2500 publications, with 26 included studies informing the narrative synthesis and model inputs. In the base case using a modified RSS the mean incremental cost was £31,900 for pooled DMTs compared with BSC and the mean incremental quality-adjusted life-years (QALYs) were 0.943, giving an ICER of £33,800 per QALY gained for people with RRMS. In probabilistic sensitivity analysis the ICER was £34,000 per QALY gained. In sensitivity analysis, using the assessment group inputs gave an ICER of £12,800 per QALY gained for pooled DMTs compared with BSC. Pegylated IFN-β-1 (125 µg) was the most cost-effective option of the individual DMTs compared with BSC (ICER £7000 per QALY gained); GA (20 mg) was the most cost-effective treatment for CIS (ICER £16,500 per QALY gained).
Limitations:
Although we built a de novo model for CIS that incorporated evidence from our systematic review of clinical effectiveness, our findings relied on a population diagnosed with CIS before implementation of the revised 2010 McDonald criteria.
Conclusions:
DMTs were clinically effective for RRMS and CIS but cost-effective only for CIS. Both RCT evidence and RSS data are at high risk of bias. Research priorities include comparative studies with longer follow-up and systematic review and meta-synthesis of qualitative studies.
Study registration:
This study is registered as PROSPERO CRD42016043278.
Funding:
The National Institute for Health Research Health Technology Assessment programme.
Contents
- Plain English summary
- Scientific summary
- Chapter 1. Background
- Chapter 2. Description of the technology under assessment
- Chapter 3. Definition of the decision problem
- Chapter 4. Methods for the assessment of clinical effectiveness
- Chapter 5. Results of the assessment of clinical effectiveness
- Search results
- Systematic reviews used to locate primary studies
- Study characteristics and methodological quality
- Clinical effectiveness: clinically isolated syndrome
- Clinical effectiveness: relapsing–remitting multiple sclerosis
- Clinical effectiveness: secondary progressive multiple sclerosis
- Overall summary of clinical effectiveness findings
- Chapter 6. Manufacturers’ submissions: clinical effectiveness
- 44 µg and 22 µg of interferon beta-1a intramuscularly three times weekly (Rebif): summary of the Merck submission
- 20 mg of glatiramer acetate subcutaneously daily or 40 mg of glatiramer acetate subcutaneously three times weekly (Copaxone): summary of the Teva Pharmaceutical Industries submission
- 30 µg of interferon beta-1a intramuscularly weekly (Avonex) and 125 µg of pegylated interferon beta-1a subcutaneously every 2 weeks (Plegridy): summary of the Biogen Idec Ltd submission
- Chapter 7. Methods for the assessment of cost-effectiveness studies
- Chapter 8. Results of the systematic review of the cost-effectiveness literature
- Chapter 9. Risk-sharing scheme submission
- Chapter 10. Manufacturers’ submissions: economic evidence
- Chapter 11. Health economic assessment: relapsing–remitting multiple sclerosis
- Chapter 12. Health economic assessment: clinically isolated syndrome
- Chapter 13. Discussion
- Acknowledgements
- References
- Appendix 1. Searches undertaken for the systematic reviews of clinical effectiveness
- Appendix 2. Sample data extraction sheet for clinical effectiveness reviews
- Appendix 3. Documentation of excluded studies
- Appendix 4. Studies included in the clinical effectiveness review with relevant publications
- Appendix 5. Overview of systematic reviews in relapsing–remitting multiple sclerosis, secondary progressive multiple sclerosis and clinically isolated syndrome: methods and results
- Appendix 6. Cost-effectiveness review of clinically isolated syndrome studies
- Appendix 7. Cost-effectiveness review of relapsing–remitting multiple sclerosis studies
- Appendix 8. Additional analyses undertaken by the assessment group
- Appendix 9. Details of resource use used to derive cost inputs
- Appendix 10. Results by age at onset of relapsing–remitting multiple sclerosis
- Glossary
- List of abbreviations
About the Series
Article history
The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 13/74/01. The protocol was agreed in July 2016. The assessment report began editorial review in September 2016 and was accepted for publication in January 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
Declared competing interests of authors
Olga Ciccarelli received consultancy fees from Novartis, Biogen Idec Ltd General Electric and Genzyme. All payments were made to her employer, the UCL Institute of Neurology. She also received reimbursement from Novartis and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) for attending a symposium and funds from the UK MS Society, Engineering and Physical Sciences Research Council (EPSRC), University College London Hospitals NHS Foundation Trust and UCL Hospitals Biomedical Research Centre for research. Aileen Clarke is an editor of the journal Health Technology Assessment. All payments are made to her employer, the Warwick Medical School. Carl Counsell received funding through Biogen Idec Ltd for a departmental multiple sclerosis (MS) nurse. He has also authored a paper that was critical of the UK risk-sharing scheme for disease-modifying therapies in MS (Sudlow CLM, Counsell CE. Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003;326:388–92). Jeremy Rodrigues holds a fellowship at the National Institute for Health and Care Excellence. This fellowship is unremunerated. Aileen Clarke and GJ Melendez–Torres are partly supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands at the University Hospitals Birmingham NHS Foundation Trust.
Last reviewed: September 2016; Accepted: January 2017.
- NLM CatalogRelated NLM Catalog Entries
- Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.[Clin Ther. 2017]Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.Soini E, Joutseno J, Sumelahti ML. Clin Ther. 2017 Mar; 39(3):537-557.e10. Epub 2017 Feb 14.
- Review The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.[Health Technol Assess. 2012]Review The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, et al. Health Technol Assess. 2012; 16(21):1-470.
- Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.[Pharmacoeconomics. 2008]Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Pharmacoeconomics. 2008; 26(7):617-27.
- Review Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages.[BMC Neurol. 2018]Review Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages.Melendez-Torres GJ, Armoiry X, Court R, Patterson J, Kan A, Auguste P, Madan J, Counsell C, Ciccarelli O, Clarke A. BMC Neurol. 2018 Oct 3; 18(1):162. Epub 2018 Oct 3.
- Review Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.[Cochrane Database Syst Rev. 2016]Review Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A. Cochrane Database Syst Rev. 2016 Nov 24; 11(11):CD009333. Epub 2016 Nov 24.
- Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer ...Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
- Clinical and cost-effectiveness of an adapted intervention for preschoolers with...Clinical and cost-effectiveness of an adapted intervention for preschoolers with moderate to severe intellectual disabilities displaying behaviours that challenge: the EPICC-ID RCT
- Timing of surgical intervention for developmental dysplasia of the hip: a random...Timing of surgical intervention for developmental dysplasia of the hip: a randomised controlled trial (Hip ’Op)
- Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Le...Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
- Provision of information about newborn screening antenatally: a sequential explo...Provision of information about newborn screening antenatally: a sequential exploratory mixed-methods project
Your browsing activity is empty.
Activity recording is turned off.
See more...